Home・Akcijų sąrašas・Alkermes PLC

Alkermes PLC

Atidarymo kaina

SektoriusSveikatos priežiūra

49.34 -1.48

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

49.05

Max

50.66

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-116M -66M
Pardavimai	8.4M 393M
P/E Sektoriaus vid.	58.589 64.641
Pelnas, tenkantis vienai akcijai	0.38
Pelno marža	-16.92
Darbuotojai	2,050
EBITDA	-98M -22M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+16.01% upside

Dividendai
By Acuity
Kitas uždarbis	2026-10-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.1B 8.8B
Ankstesnė atidarymo kaina	50.82
Ankstesnė uždarymo kaina	49.34

Naujienos nuotaikos

By Acuity

10%

90%

5 / 340 reitingas Healthcare

Alkermes PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 20:02; UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

2026-07-31 19:36; UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2026-07-30 19:58; UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

2026-07-29 20:03; UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

2026-07-28 20:02; UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

2026-07-24 19:46; UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

2026-07-22 19:36; UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

2026-07-21 18:46; UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

2026-07-20 22:01; UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Alkermes PLC Prognozė

Kainos tikslas

By TipRanks

16.01% į viršų

12 mėnesių prognozė

Vidutinis 57.46 USD 16.01%

Aukščiausias 65 USD

Žemiausias 38 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Alkermes PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių Alkermes PLC akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

5 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.